Abstract:Background and purpose: In clinical studies, checkpoint inhibitor-related pneumonitis (CIP) ranks first among the causes of death in programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor immune-related adverse events. Real-world CIP situations lack extensive population reports. This study aimed to understand the incidence of CIP in the real world of lung cancer in China, and to summarize its characteristics, treatment status and outcomes. Methods: This study retrospectively collected the essential clinical information of patients with an initral diagnosis of lung cancer who received treatment with immune checkpoint inhibitors (ICIs) at the First Affiliated Hospital of Guangzhou Medical University and Shanghai Pulmonary Hospital between January 2019 and September 2021. For patients with CIP, we also collected the time of its onset, grade, treatment regimen and outcome. The analyses of incidence, patient’s characteristics and the risk factors of CIP in overall and subgroup were carried out. Moreover, we analyzed the outcomes of patients treated with immunosuppressive therapy. Results: A total of 2 031 patients with immunotherapy were enrolled, with a CIP incidence rate of 7.2% (147/2 031), a severe CIP rate of 2.6% (52/2 031) and a mortality rate of 0.4% (9/2 031). The rate of severe grade in the population with CIP was 35.4%, and the mortality rate was 6.1% (9/147). Compared with non-CIP patients, more CIP patients were male, older (>65 years), with combination therapy, and on first- and second-line immunotherapy in advanced treatment. In subgroup analyses, the incidence of CIP was higher in men, the elderly (>65 years), squamous cancer, combination therapy, anti-PD-1 inhibitors, and first- and second-line therapy in advanced treatment. The median onset time of CIP in the real world was 148 days, with a double-peak characteristic, that was, 60-90 days and 150-210 days after immunotherapy were both the peak time periods for CIP onset. The incidence of CIP was also influenced by seasonality, with a high incidence in autumn and winter. All treated patients used corticosteroids as first-line treatment; the immunosuppressive treatment rate of CIP in this study was 76.2%. After treatment, 97.9% of mild CIP patients and 81.2% of severe CIP patients had a good prognosis, and 17.3% of severe CIP patients died due to CIP. Conclusion: In the real world, the incidence of CIP for lung cancer patients was 7.2%, incidence of severe CIP was 2.6%, and mortality rate was 0.4%; the incidence of severe disease in the population with CIP was 35.4%, and mortality rate was 6.1%. The median onset time of CIP was characterized by a double peak, and incidence of CIP was higher in autumn and winter. Men, the elderly, squamous cancer patients, patients on combination therapy, patients who used anti-PD-1 inhibitors, and patients with advanced treatment had higher incidence of CIP. Most patients with CIP had good outcomes after immunosuppressive therapy.

Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Development and Validation of a Risk-Prediction Model for Immune-Related Adverse Events in Patients with Non-Small-cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.

Difficulty in differentiating liver injury from an immune checkpoint inhibitor from chemotherapy

New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury

Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer

Clinical Features and Risk Factors for Drug-Induced Liver Injury: A Retrospective Study From China

Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy

Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer

The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials

P2.01-30 Hepatitis B Infection or Aminotransferase Increase Associate with Poor Outcome of Anti-PD-1 Monotherapy in Patients with Advanced NSCLC

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors

Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience

A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer

Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study

Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta‐Analysis

Analysis of Toxicity Profile and Predictors of Immune Checkpoint Inhibitor-Related Adverse Events

Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China